BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2026 5:51:08 AM | Browse: 22 | Download: 85
 |
Received |
|
2025-12-11 02:28 |
|
Peer-Review Started |
|
2025-12-11 02:28 |
|
First Decision by Editorial Office Director |
|
2026-01-07 10:05 |
|
Return for Revision |
|
2026-01-09 07:06 |
|
Revised |
|
2026-01-20 10:06 |
|
Publication Fee Transferred |
|
2026-01-22 09:40 |
|
Second Decision by Editor |
|
2026-03-05 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-05 08:03 |
|
Articles in Press |
|
2026-03-05 08:03 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-19 06:39 |
|
Publish the Manuscript Online |
|
2026-03-26 05:51 |
| ISSN |
1949-8470 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Retrospective Study |
| Article Title |
Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Yan Zhang, Yu-Kun Li, Zi-Bin Tian, Qing-Yu Guo, Jing-Nong Liu, Rui-Qing Liu and Ke-Yu Ren |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ke-Yu Ren, Department of Gastroenterology, The Affiliated Hospital of Qingdao University, No. 1677 Wutaishan Road, Qingdao 266000, Shandong Province, China. renkeyuqd@126.com |
| Key Words |
Ulcerative colitis; Vedolizumab; Therapeutic response; Inflammatory markers; Body composition |
| Core Tip |
Combined assessment of intramuscular adipose tissue, C-reactive protein levels, skeletal muscle mass and hemoglobin status can effectively predict vedolizumab response in ulcerative colitis patients. Routine screening of these markers helps identify potential non-responders early, optimize individualized treatment regimens, and improve clinical management efficiency of ulcerative colitis. |
| Publish Date |
2026-03-26 05:51 |
| Citation |
Zhang XY, Li YK, Tian ZB, Guo QY, Liu JN, Liu RQ, Ren KY. Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers. World J Radiol 2026; 18(3): 117599 |
| URL |
https://www.wjgnet.com/1949-8470/full/v18/i3/117599.htm |
| DOI |
https://dx.doi.org/10.4329/wjr.v18.i3.117599 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
